Letter

Alosetron for irritable bowel syndrome

BMJ 2003; 326 doi: 10.1136/bmj.326.7379.51/b (Published 4 January 2003)
Cite this as: BMJ 2003;326:51.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Senior vice president of GlaxoSmithKline responds

  1. James B D Palmer, senior vice president, new product development (jbdp0056@gsk.com)
  1. GlaxoSmithKline, 5 Moore Drive, Research Triangle Park (RTP), NC 27709, USA
  2. Forest Laboratories, 909 Third Avenue, New York, NY 10022, USA

    EDITOR—As the senior doctor at GlaxoWellcome and GlaxoSmithKline who participated in all of the key meetings that resulted in the withdrawal of Lotronex (alosetron) and the subsequent approval for reintroduction, I feel compelled to reply to both the article and editorial on alosetron. 1 2

    Moynihan sees a complex web of intrigue where none existed, at least from the viewpoint of GlaxoWellcome and GlaxoSmithKline.1 Here are the key elements of the story from our position.

    We had a medical disagreement with the Food and Drug Administration about the aetiology of the serious adverse events occurring in patients taking alosetron. In November 2000 we had several meetings with the administration, which led to a meeting on 28 November where we realised we could not come to agreement …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular